The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
Kerry Rogers
• 19 Jun 2019
The combination of acalabrutinib with obinutuzumab was investigated for the treatment of chronic lymphocytic leukemia (CLL) in the Phase 1b/2 ACE-CL-003 study (NCT02296918). Here, Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the 3-year follow-up. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
